PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myeloma The P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…

BySenior EditorMay 2, 2022

Top Performing Drug of 2021 – Humira (April Edition)

Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…

BySenior EditorApril 29, 2022

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years. No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

BySenior EditorApril 28, 2022

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

Top Performing Drug of 2021 – Humira (April Edition)

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

Contact US

FOLLOW US